



Version of attached le:
Accepted Version
Peer-review status of attached le:
Peer-reviewed
Citation for published item:
Jiang, L. and Lan, R. and Huang, T. and Chan, C. and Li, H. and Lear, S. and Zong, J. and Wong, W. and
Lee, M.M. and Chan, B.D. and Chan, W. and Lo, W. and Mak, N. and Lung, M.L. and Tsao, S.W. and
Taylor, G.S. and Bian, Z. and Tai, W.C.S. and Law, G. and Wong, W.T. and Cobb, S.L. and Wong, K.L.
(2017) 'EBNA1-targeted probe for the imaging and growth inhibition of tumours associated with the
EpsteinBarr virus.', Nature biomedical engineering., 1 . 0042.





The full-text may be used and/or reproduced, and given to third parties in any format or medium, without prior permission or charge, for
personal research or study, educational, or not-for-prot purposes provided that:
• a full bibliographic reference is made to the original source
• a link is made to the metadata record in DRO
• the full-text is not changed in any way
The full-text must not be sold in any format or medium without the formal permission of the copyright holders.
Please consult the full DRO policy for further details.
Durham University Library, Stockton Road, Durham DH1 3LY, United Kingdom




EBNA1-targeted probe for the imaging and growth inhibition of tumours associated with 
the Epstein-Barr virus 
Lijun Jiang1, Rongfeng Lan1, Tao Huang2, Chi-Fai Chan3, Hongguang Li1, Sam Lear4, Jingyi 
Zong4, Wing-Yan Wong3, Magnolia Muk-Lan Lee3, Brandon Dow Chan3, Wai-Lun Chan1, Wai-
Sum Lo3, Nai-Ki Mak5*, Maria Li Lung6, Hong Lok Lung5, Sai Wah Tsao7, Graham S. Taylor8, 
Zhao-Xiang Bian2, William C. S. Tai3, Ga-Lai Law3*, Wing-Tak Wong3*, Steven L. Cobb4*, and 
Ka-Leung Wong1* 
a. Department of Chemistry, Hong Kong Baptist University, Kowloon Tong, Hong Kong  SAR, 
China. 
b. Department of Biology, Hong Kong Baptist University, and Centre for Nasopharyngeal 
Carcinoma Research, University of Hong Kong, Hong Kong SAR. 
c. Clinical Division, School of Chinese Medicine, Hong Kong Baptist University, Kowloon 
Tong, Hong Kong SAR, China.  
d. Department of Chemistry, Durham University, Durham DH1 3LE, UK. 
e. State Key Laboratory of Chiroscience, Department of Applied Biological and Chemical 
Technology, Hong Kong Polytechnic University, Hung Hum, Hong Kong SAR, China. 
f. Department of Clinical Oncology, University of Hong Kong, and Cancer for Nasopharyngeal 
Carcinoma Research, University of Hong Kong, Hong Kong SAR;  
g. School of Biomedical Sciences, University of Hong Kong, Hong Kong SAR;  









Epstein-Barr Nuclear Antigen 1 (EBNA1), a dimeric oncoprotein of the Epstein-Barr virus (EBV), 
is essential for both viral-genome maintenance and the survival of infected cells. Despite EBNA1’s 
potential as a therapeutic target, tools for the direct monitoring of EBNA1 in vitro and in vivo are 
lacking. Here, we show that a peptide-based inhibitor that luminesces when bound to EBNA1 
inside the nucleus of EBV+ cells can regulate EBNA1 homodimer formation and selectively 
inhibit the growth of EBV+ tumours of nasopharyngeal carcinoma C666-1 cells, NPC43 cells and 
Burkitt’s lymphoma Raji cells. We also show that the peptide-based probe leads to 93% growth 
inhibition of EBV+ tumours in mice. Our findings support the hypothesis that selective inhibition 
of EBNA1 dimerization can be used to afford better EBV-related cancer differentiation, and 
highlight the potential application of the probe as a new generation of biotracers for investigating 








Epstein-Barr virus (EBV) is a ubiquitous human herpes virus which causes both infectious 
mononucleosis and lymphoproliferative diseases1,2, but the virus is well controlled by the immune 
system once it establishes latent infection in human hosts3,4. Epstein-Barr nuclear antigen 1 
(EBNA1) is the only oncoprotein expressed in all EBV-positive tumours and it plays critical roles 
in the maintenance, replication and transcription of the EBV genome. Furthermore, it can influence 
cellular gene transcription which is fundamental in the development of EBV-related tumours5. 
Given these key biological functions, EBNA1 has become an attractive target for therapeutic 
intervention6,7. Considering that homodimerization of EBNA1 is essential for EBNA1 to function, 
inhibitors which can specifically prevent the dimerization process offer a novel avenue by which 
to target and kill EBV-positive cells8,9. Several EBNA1 inhibitors have been reported to efficiently 
block EBNA1 homodimerization, including the small molecule, EiK1, and a short EBNA1 derived 
peptide (P85). Eik1 was identified via high-throughput screening, and it is capable of targeting the 
dimeric interface of EBNA1 (residues 459-607), P85 which contains a short EBNA1 derived 3 
sheet (a.a. 560-566) also targets this region (residues 560-574)8. However, most of the EBNA1 
targeting compounds that have been reported to date cannot be easily imaged (in vitro) and they 
have low bioavailability. Both the aforementioned issues present major challenges to the field and 
hamper the further development of EBNA1 targeting therapeutics. To overcome the non-
fluorescent nature and poor water solubility of the previously reported EBNA1 inhibitors, we 
recently designed a novel hybrid system, which contained a charged, water-soluble chromophore 
and an EBNA1-specific peptide. The charged, water-soluble chromophore-peptide bio-conjugate, 
JLP2, enabled for the first time both simultaneous specific imaging and inhibition of EBNA1 in 





binding which limited its further development as a tool for cellular imaging, and, as a potential 
selective therapeutic agent for the treatment of EBV cancers. 
It is also worth noting that EBNA1 is primarily localized in the nucleus of EBV-positive cells10, 
and EBNA1 acts as a bridge between mitotic chromosomes and oriP-containing plasmids11. One 
factor that has limited the success of cancer therapies is the challenging associated with specifically 
targeting a desired cell type12. Despite the key role and the specific localization of EBNA1, a direct 
and sensitive system for visualizing EBNA1 in the nucleus and monitoring its effect on EBNA1 
homodimerization is not currently available. To address this problem, we reasoned that valuable 
new insights and selective tumour inhibition both in vitro and in vivo could be gained if a nucleus-
penetrating EBNA1-specific dual-probe could be developed. The development of responsive 
nucleus-specific bioprobes for in vitro microscopic studies of EBNA1 and selective inhibition on 
EBV-positive tumour has not yet been explored in detail. The work reported here offers a strategy 
for responsive-emission imaging in EBV-positive cells and provides highly selective and efficient 
in vitro/vivo cytotoxicity. 
The rationale design (Fig. 1a) of the dual functioning probe was achieved using docking and 
molecular dynamic (MD) simulations and their synthesis was outlined in Sup. Fig. 1. The 
characterization of all intermediates and final products, including 1H NMR, 13C NMR and Mass 
Spectra, were performed as shown in Sup. Fig. 37-48. What’s more, the peptide conjugates were 
purified via HPLC, the purification and characterization was recorded in Sup. Fig. 2-6, the used 
solvent gradient was also recorded (Sup. Table 1 and 2). The strong interaction of L2P4 with the 
wild type EBNA1 (WT-EBNA1) was confirmed by a 8.8-fold increase in its emission intensity. 
L2P4 responded significantly upon binding with WT-EBNA1, and the responsive signal was found 





imaging and control of the growth of EBV-positive tumours have been achieved by our designed 
dual-function fluorescent probes through selective interference of EBNA1 homodimerization. 
L2P4 displayed excellent cytotoxicity towards EBV-positive cells (IC50 ~ 15 M), and minimal 
cytotoxicity against EBV-negative cells even at high doses (50 M). Furthermore, L2P4 
demonstrated excellent in vivo toxicity against EBV-positive tumours (intra-tumour injection of 4 
g gives 92.8% growth inhibition).  
Both the in vitro and in vivo studies described here demonstrated the effectiveness of L2P4 as a 
dual EBV tumour-selective cancer targeting agent and responsive imaging probe. Given these 
findings, we envisage that L2P4 represents an efficient tool to delineate the processes that govern 
EBNA1 within the nucleus. In the longer term this new level of understanding will provide exciting 
new opportunities for the treatment of EBV-associated tumours, such as Hodgkin lymphoma, 








Rational design and MD simulations between probes and EBNA1. The X-ray crystal structure 
of EBNA1’s DNA-binding domain (DBD) (PDB ID: 1B3T, chain A, residue 461 to 607) is α/β 
mixed fold comprised of 4 alpha helix and 4 beta sheet motifs which are linked by several loops 
(Fig. 1b and Sup. Fig. 7)13. Different structural motifs contribute to its distinct functional regions: 
the beta sheets 1-4 (β1-β4) drive the formation of dimer via hydrophobic packing; the alpha helices 
1 and 2 (α1, α2) interact with DNA via electrostatic interactions, while the alpha helices 3 and 4 
(α3, α4) stabilize the beta sheets; the positively-charged loop 1 mediates DNA binding; and the 
flexible loop 5 also involves in the dimerization14.  
The putative structure of EBNA1 DBD monomer was generated through the isolation from the X-
ray crystal structure of its homodimer, and it was performed for a 200 ns all-atom explicit solvent 
MD simulations. The putative structure demonstrated a good stability and kept the original 
conformation during the simulation, except for the highly dynamic loop 1 and 5 which have no 
contribution in the homodimerization of EBNA1 (Sup. Fig. 8a, 8b). What’s more, the 4 beta sheets 
which comprise the dimeric interface were also found to exhibit good stability (Sup. Fig. 8c). It 
was further evaluated for the accessibility of the dimeric interface in the putative structure, and the 
results suggested that the key residues (Y561, M563, and F565) on the dimeric interface
8 could be 
assessed by extrinsic probes (Sup. Fig. 8d). After checking the stability and accessibility of this 
putative structure, a representative conformation was selected out and the docking study was 
carried out to identify the best docked poses for each ligand-EBNA1complex (Sup. Fig. 8e, 8f). 
All docked poses were then ranked using a scoring function to choose the final poses for each 
complex. It was found most selected poses sharing some extend similarities, for example, the 





Besides, an unexpected salt-bridging was found between the positively-charged tetrapeptide RrRK 
and the aspartate-rich tail in EBNA1, suggesting a second role of the NLS. 
To better characterize the ligand-EBNA1 complex and calculate their binding energy, a 200 ns 
MD simulations were then performed using the selected docked poses. The AMBER types of the 
non-standard residues were parameterized (Sup. Fig. 10) and the missing force filed parameters 
were defined (Sup. Table 3) prior to the following 200 ns MD simulations. All complexes were 
found to be stabilized after 50 ns, and it is hard to find a conserved binding pattern between them 
though sharing a same motif (YFMVF), and it is due to the affection of the salt-bridging interaction 
which appeared only in the ligands containing the RrRK tetrapeptide. Despite these, the main 
interactions suggested by MD simulations for each complex were similar (i.e. the clear 
hydrophobic contacts and the salt-bridging, Sup. Fig. 17). The hydrophobic interactions identified 
occurred between the key residues on the dimeric interface and the ligands, while the salt bridging 
was formed between the RrRK motif and several residues in the aspartate-rich tail in EBNA1 (D602, 
D601 and D605). In particular, D602 demonstrated the strongest salt bridging interaction and D605 
showed the weakest (Sup. Fig. 11-16). Taken as a whole, the MD simulations suggested two major 
interaction type which facilitate the binding of the designed probes to EBNA1, and they also, 
demonstrated a secondary role of the RrRK sequence beyond nuclei targeting (Fig. 1b). 
The binding free energy for all complexes was calculated via Molecular Mechanics Poisson-
Boltzmann Surface Area (MMPBSA) based on full trajectory. The calculated GB and PB values 
took the same order L2P4 > L2P3 > L2P2 (Fig. 1c and Sup. Table 4), indicating that L2P4 is likely 
to have the strongest binding interaction among the three probes to EBNA1. 
It should be noted that an X-ray crystal structure of the EBNA1 monomer has not yet been solved 





simulations. In addition the rigid protein model used in the MOE-Dock approach, the implicit 
solvent environment in the docking experiment and an untrained scoring function for the protein-
peptide case, may also introduce errors into the determination of the initial structures and thus into 
the subsequent MD simulations. The aforementioned points highlight that the numerical results 
generated in the MD simulations for the proposed protein-ligand complex structures should be 
viewed as indicative rather than definitive values. However, despite any potential error in the 
specific values calculated the overall binding trends for the ligands predicted computationally are 
also clearly seen experimentally (e.g. L2P4 was validated experimentally to have the strongest 







Responsive emission of L2P4 with EBNA1. The stability of L2P2-L2P4 was performed by 
monitoring their emission spectrum at 37 C during 24 hours, and all probes demonstrated a good 
stability in the simulated extra cellular anion mixture (PBS buffer) (Sup. Fig. 18). As discussed 
from the MD simulations and free energy calculations, L2P4 was predicted to have the strongest 
interaction with WT-EBNA1 of the three probes studied, and thus it potentially offered the best 
option by which to prevent the homodimerization of EBNA1 and ultimately inhibit the growth of 
EBV-positive tumour. To further assess the binding affinity of L2P4 to WT-EBNA1, luminescence 
titration experiment was carried out in PBS buffer. The results obtained from the titration 
experiment aligned well with the calculated data via MMPBSA. For example, L2P4 was found to 
have the strongest responsive signal upon the addition of WT-EBNA1 (Fig. 2a, 2b, 2c, Sup. Fig. 
21), a 8.8-fold emission enhancement (ϕinitial = 4 %, ϕ4M WT-EBNA1 = 23%, Sup. Fig. 19 and 20) and 
25 nm emission blueshift. A 4.7 times emission enhancement was seen in the titration experiment 
for L2P3, and no emission enhancement/quenching was observed for L2P2 upon addition of 4 M 
WT-EBNA1 (Sup. Fig. 21). The affinity strength for a probe to its binding protein can be defined 
as the binding constant and binding ratio. The aforementioned binding constant (log Ka) was 
calculated for L2P2-L2P4 to WT-EBNA1 (Sup. Fig. 21). The logarithm of the fluorescence ratio 
demonstrated a linear relationship with that of the protein concentration. The value of log Ka was 
calculated to be 5.50 and 6.82 for L2P3 and L2P4 respectively, and both of the binding ratios were 
found to be 1:1. Considering the strongest binding of L2P4 to WT-EBNA1, we then further 
investigated the binding selectivity of L2P4 to WT-EBNA1 in the presence of various proteins (Fig. 
2c) and biologically relevant metal ions/small molecules (Zn2+, citrate etc) (Sup. Fig. 22, 23). The 
proteins analyzed in the selectivity assay included four EBNA1 mutant proteins and bovine serum 





(yielding EBNA1-3A) or via conservative point mutation of Y561, M563, and F565 to A (yielding 
EBNA1-Y561A, EBNA1-M563A and EBNA1-F565A). The selectivity of L2P4 for each protein was 
investigated by recording changes in its emission. A relatively slight emission enhancement was 
observed (Fig. 2c) upon addition of the four mutant EBNA1 proteins and BSA, suggesting a 
weaker binding of L2P4 to the aforementioned proteins when compared to the results obtained in 
the titration experiments with WT-EBNA1 (log Ka for EBNA1-Y561A, EBNA1-M563A, EBNA1-
F565A and EBNA1-3A is 5.1, 3.6, 4.3, 3.9 respectively, and for BSA is 4.7). 
It is well established that when an environment-sensitive fluorophore is conjugated to peptides 
with specific targeting, subsequent protein binding will give rise to the emission intensity and a 
strong blue-shift will occur due to the dramatic change in excited state dipole-moments. It is well 
known now that the dual fluorescence of 4-(N,N-dimethylamino)benzonitrile (DMABN) arises 
due to an emission from the local excited (LE) state and an “anomalous” red-shifted emission from 
the ICT state15-17. Among the numerous DMABN analogues reported to date, pyridine derivatives 
have been a focus of particular interest, especially in the determination of cell microviscosity18. 
With this in mind we proposed that a fluorescent probe consisting of an ICT state pyridine 
derivative fluorophore and a nucleus-permable EBNA1-specific peptide, which generates ICT 
characterized emission after binding with EBNA1, could prevent the homodimerization of EBNA1, 
and meanwhile imaging on nucleus level in EBV-positive cells. 
The absorption spectrum of L2P4 was measured in various solvents (Sup. Fig. 24). The spectra 
showed two absorption bands at 274 nm and ~500 nm, which corresponded to the transition from 
ground state to LE and ICT states, respectively17, 19. The maximum absorption band was slightly 
red-shifted in polar solvents. L2P4 demonstrated dual fluorescence upon excitation, a weak but 





the ICT state were both observed (Fig. 2a, 2d, 2e). The fluorescence emission of LE band was 
solvent-independent, while the ICT band exhibited a marked dependence on solvent polarity, 
progressively blue shifted with the decreasing of solvents polarity (Fig. 2e). Besides, the emission 
decay of L2P4 was measured as shown in Sup. Fig. 26 and Fig. 2f (upper, ex = 475 nm, monitored 
at 625 nm) and the emission lifetime of L2P4 in different solvents was concluded in Sup. Table 5. 
The observed shorter lifetime (~0.5 ns) was corresponded to the LE emission, and the ICT band 







Nuclear in vitro imaging of L2P4. The in vitro imaging of L2P2, L2P3 and L2P4 in HeLa, CNE2, 
C666-1 and NPC43 cells were carried as shown in figure 3. HeLa is EBV-negative human cervical 
carcinoma cell line, CNE2 is EBV-negative nasopharyngeal carcinoma cell line, C666-1 is EBV-
positive nasopharyngeal carcinoma cell line, and NPC43 is the newly derived EBV-positive 
nasopharyngeal carcinoma cell line which was established from a surgical resected NPC tissue 
from a male patient (64 years old with Stage III recurrent NPC). As previously discussed, we 
incorporated a NLS sequence RrRK into P3 and P4 to help their nucleus permeability20, 21. The 
cellular uptake and localization of the three probes was evaluated independently using confocal 
imaging and flow cytometry (Fig. 3, Sup. Fig. 28, 29, 30). From these experiments, L2P4 was 
found to have a better cellular uptake compared with the other two probes in both HeLa and C666-
1 cells (Sup. Fig. 28). With the significant contribution of RrRK, the subcellular localization of 
L2P3 and L2P4 can be observed in the nucleus of EBV-positive cells (C666-1 and NPC43 cells), 
whilst L2P2 can only be noticed in cytoplasm in the tested cells, suggesting L2P3 and L2P4 could 
localize on the EBV-positive cell-nucleus. In addition, two videos of L2P4 in HeLa and C666-1 
cells were performed (Conc.: 10 M) (Sup. Video 1 and 2). Images in the video were taken once 
per minute and 60 images for the first hour after drug treatment were collected to make the video. 






Selective toxicity of L2P4 towards EBV+ cells. EBNA1 can only facilitate DNA replication of 
EBV by forming homodimers, thus blocking dimer formation provides a route by which to kill 
EBV-infected tumour cells. As is well known, the EBNA1 dimer is formed through the YFMVF-
mediated interface, and this can be examined by MBS (3-maleimidobenzoyl N-
hydroxysuccinimide ester, an amine-to-sulfhydryl crosslinker that contains NHS-ester and 
maleimide reactive groups) cross-linked dimerization assay. The MBS mediated protein 
crosslinking effect was represented as a ratio of dimer/monomer. The importance of YFMVF on 
dimerization was further investigated in the WT-EBNA1 and EBNA1 mutants (EBNA1-Y561A, 
EBNA1-M563A, EBNA1F565A and EBNA1-3A) by its homodimerization efficiency. The results 
demonstrated that the dimerization efficiency was greatly decreased in EBNA1-3A, and also, a 
relative slight decreasing in the efficiency was observed in the other three point mutants (Sup. Fig. 
27). Consistent with this observation and the luminescence titration experiment, the MBS cross-
linked dimerization assay was also obviously inhibited by the designed probes as shown in Fig. 4a, 
4b, 4c, 4d (P<0.001). 
Considering the strong binding of L2P4 to WT-EBNA1 and the selective nuclear in vitro imaging, 
we sought to evaluate if L2P4 could deliver selective and efficient cytotoxicity towards EBV-
positive cells. The MTT cytotoxicity assay of the three peptides (P2-P4, Sup. Fig. 31) and three 
peptide conjugates (L2P2-L2P4, Fig. 4e-4j) was carried out in three kinds of EBV-negative (MRC-
5, HeLa and Ramos) cells and three EBV-positive (C666-1, NPC43 and Raji) cells. All probes 
were found to have weak cytotoxicity in EBV-negative cells even at high doses (50 M), and they 
all exerted dose-dependent cytotoxicity in EBV-positive cells. Furthermore, L2P4 demonstrated 





the three probes in EBV-positive cells was in the same order as the findings in 200 ns MD 







In vivo tumour imaging and inhibition of L2P4. To further evaluate the in vivo performance of 
L2P4, the intra-tumoural injections of P4/L2P4 in two dosage amount (2 g Low Dosage (L) and 4 
g High Dosage (H)) in BALB/c nude mice carrying C666-1 and HeLa cell xenografts have been 
performed, injections were carried out biweekly with body weight and tumour measurements, mice 
carrying HeLa cell xenografts served as control to confirm the specific in vivo targeting effect of 
P4/L2P4. Treatment with P4/L2P4 on mice had no significant effects on body or organ weights 
when compared to control (Sup. Fig. 32, 33, 35a), indicating that neither P4 nor L2P4 exhibit a 
toxic effect in vivo. C666-1 cell xenograft growth was effectively inhibited while the growth of 
HeLa cell xenograft was unaffected by treatment with P4/L2P4 (Fig. 5d, Sup. Fig. 35b). By day 7, 
treatment with P4-L, P4-H and L2P4-H on C666-1 cell xenografts has led to significant decreases 
in tumour volume and at the end of the experiment (day 21), the average tumour volumes of mice 
were decrease by 65.7%, 65.5% and 92.3% (P<0.05, P<0.005 and P<0.001) respectively, when 
compared to control (Fig. 5d, Sup. Fig. 34). In the HeLa cell xenografts, there was no significant 
difference in the average tumour volume of mice treated with P4/L2P4 (low or high dose) and 
control after 18 days (Sup. Fig. 35b). At the end of the experiment, mice were sacrificed and 
tumours were excised and weighed, average tumour weights were decreased on C666-1 cell 
xenografts after treatment with P4-L, P4-H and L2P4-H by 72.6%, 86.6% and 92.8% (NS, P<0.05 
and P<0.005) respectively, when compared to control (Fig. 5a, 5b, 5c and 5e). While in the HeLa 
cell xenografts, there was no obvious difference in the average tumour weights (Sup. Fig. 35c, 36). 
The significant and selective inhibition of P4/L2P4 on EBV-positive tumour confirmed their EBV-





Furthermore, the fluorescence imaging of the excised C666-1 tumours confirmed the fluorescence 
from L2P4 treated tumours (Fig. 5f), indicating the presence of signal 48 hours post-intra-tumoural 








Our initial MD studies suggested that a network of hydrophobic interactions and salt bridging mediates the 
binding of L2P4 to the dimeric interface of EBNA1 (Fig. 1). The selective and strong binding of L2P4 to EBNA1 
was further confirmed using luminescence titration experiment (Fig. 2). L2P4 was found to localise in the nucleus 
of EBV-positive cells, but not that of EBV-negative cells. The observed selective emission of L2P4 on nucleus 
was generated by its binding with EBNA1 (Fig. 3). 
Our study also revealed that EBNA1 mutants (especially EBNA1-3A) were not able to undergo homodimerization 
(Sup. Fig. 27), emphasizing the importance of the dimeric interface (YFMVF) on EBNA1 dimer formation. The 
analysis of the WT-EBNA1 dimerization efficiency upon addition of the designed probes using a MBS cross-
linked dimerization assay showed that the probes can significantly interfere with EBNA1 dimer formation (Fig. 
4a, 4b, 4c, 4d). Extensive cytotoxicity assays performed against both EBV positive and negative cells 
demonstrated the significant and selective inhibition of L2P4 on EBV-positive cells, more importantly, revealed 
the reason for the selective cytotoxicity is the inhibition on EBNA1 dimerization process (Fig. 4e-4j). Finally, 
studies of L2P4 on mice carrying C666-1 and HeLa cell xenografts confirm that it has EBV-targeting specificity 
and indicated that our designed probe can be successfully applied to target and inhibit the growth of EBV-positive 
tumours in vivo (Fig. 5). 
Our data clearly demonstrates that L2P4 can selectively inhibit EBV-positive tumours-both in vitro and in vivo, 
and that it does this via interfering with EBNA1 homodimerization. We are confident that our present work will 
revive research interest and open new doors in the study of EBNA1 inhibition by shining light onto previously 
unknown areas – visualization of the binding of probe with EBNA1 and the dimerization inhibition process on 
EBV-positive cell nucleus, with L2P4 as a solid foundation for further development against EBV-related 
malignancies with emphasis put on EBNA1-related factors such as Zn2+, followed by realization of these probes 







Molecular dynamics simulation. All the simulations reported herein were performed with the unbiased MD 
program in Amber 14. The ff99SBildn force field22 has been used to describe all molecular systems. For each of 
the simulations, the peptide was solvated in a periodic truncated cubic box with TIP323 water molecules, providing 
10 Å buffer distance between the peptide surface and the periodic box edge. The peptide was then heated from 
100 K to 300 K in 20 ps. The system was further equilibrated in 200 ps with constant pressure and temperature 
(NPT) before stating the 200 ns NPT production simulation. A 2 fs time step and SHAKE-enabled setting were 
applied during the equilibration and production stages, and Berendsen thermostat was used for temperature 
controlling. Detailed MD simulations of peptides/probe-EBNA1 complexes can be found in Supplementary 
Materials. 
Luminescence titration analysis. The measurement of the binding constant and selectivity of the designed 
probes was performed by luminescence titration analysis. It was conducted with gradually addition of various 
analytes (e.g. WT-EBNA1, EBNA1 mutants, BSA and metal ions), which will be ceased either when the volume 
of added analytes totalled 5% of the probes or the influence on luminescence was saturated. 
Protein samples preparation. Five protein samples were used during this work. WT-EBNA1 protein (379-641 
a.a.) fused with glutathione S-transferase was expressed in Escherichia coli and purified by glutathione sepharose 
4B rinse (GE Healthcare Dharmacon), afterwards 5 g EBNA1 was prepared and incubated with MBS at 37C 
for 10 minutes. The protein was separated on an SDS-PAGE gel, transferred onto the nitrocellulose membrane 
and blotted by antibodies (#RG001040, Solarbio, Bioscience & Technology Co., LTD). EBNA1 mutant proteins 
were prepared by mutation of YFMVF to FFAVA (yielding EBNA1-3A mutant) or conservative point mutation 
of Y561, M563, F565 to A (yielding EBNA1-Y561A, EBNA1-M563A and EBNA1-F565A) through site-directed 
mutagenesis. 
Cell culture. The EBV-negative MRC-5 and HeLa cells were provided by the Shanghai cell bank, Chinese 
Academy of sciences; the EBV-negative nasopharyngeal carcinoma CNE2 and EBV-positive nasopharyngeal 






Burkitt’s lymphoma Ramos and EBV-positive Burkitt’s lymphoma Raji cells were afforded by H. L. Lung; the 
newly derived EBV-positive nasopharyngeal carcinoma NPC43 cells were contributed by S. W. Tsao. 
MRC-5 (normal lung fibroblasts) cells were grown in Minimum Essential Medium (MEM); HeLa (cervical 
carcinoma) cells were grown in Dulbecco’s Modified Eagle Medium (DMEM); CNE2 and C666-1 
(nasopharyngeal carcinoma), Ramos and Raji (Burkitt’s lymphoma) cells were grown in Roswell Park Memorial 
Institute (RPMI)-1640 medium. All medium used was supplemented with 10% fetal bovine serum (FBS), 1% 
penicillin and streptomycin at 37C and 5% CO2. NPC43 cells were maintained in RPMI1640 with 10% serum 
and 4 M ROCK inhibitor Y27632 ROCK (Enzo Life Sciences). 
NPC43 cells were established from a surgical resected NPC tissue from a male patient, 64 years old with Stage 
III recurrent NPC. The NPC43 cell harbour EBV virus and was kept in RPMI supplemented with 10% FBS and 
4 M of a Rho kinase inhibitor, Y27632 over 200 population doublings. The NPC43 is tumourigenic when 
injected at subcutaneous site (10 million cells) of NOD/SCID mice. STR profiling confirms its origin from the 
NPC patients. The NPC43 cells could be induced to under lytic reactivation of EBV by treatment with 
TPA/sodium butyrate and infectious EBV could be harvested from supernatant of NPC43 cells. All cell line used 
in the current study were tested and confirmed to be mycoplasm-negative, and authenticated by using the 
AmpFℓSTR Identifier PCR Amplification kit (Life Technologies). 
Flow cytometry analysis. HeLa and C666-1 cells (105 per sample) were seeded to 35 m Petri dishes overnight. 
Afterwards, the cells were incubated with the probes as indicated, and then washed with PBS several times. 
Cellular uptake was evaluated with flow cytometry under 488 nm excitation generated by an argon laser. The 
emission was obtained by using FL2-H (log). 10000 events were analyzed to get the cellular uptake. 
In vitro imaging and Co-staining. Cells were incubated for 6 hours before monitoring/imaging. For co-staining 
experiments after incubation cells were further treated with 1nM nucleus lyso Green DND-26 tracker/mito Green 
FM M7514 tracker/Hoechst 33342 nuclear dye for 1 hour. Imaging was conducted with a commercial multi-





nm, 457 nm and 488 nm), He-Ne laser (632 nm), UV-lamp and controlled CO2 content stage-top tissue culture 
chamber (2-7 % CO2, 37C). 
Cytotoxicity test. The MTT viability assay was performed according to standard methods. In brief, cells (3103/ 
well) were seeded in 96-well plates 24 hours prior to exposure to the probes. The cells were incubated with the 
probes in the dark for another 24 hours. The cytotoxicity was determined by the MTT reduction assay. The cell 
monolayers were rinsed with phosphate-buffered saline (PBS) and then incubated with 50 uL MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] solution (0.5 mg/ mL) at 37C for 3 hours. Then the 
media were removed, and 100 uL of DMSO solubilizing reagent was added and shaken for 30 minutes to dissolve 
the formed formazan crystals in the living cells.  
Nude mice carrying C666-1/HeLa xenograft and intra-tumoural injection (HeLa xenografts served as 
control). C666-1/HeLa cells (1 × 107) were suspended in serum free medium (C666-1) or mixed 1:1 with Matrigel 
(HeLa) to a final volume of 150μl and injected into the right flanks of male (C666-1) or female (HeLa) 6- to 8-
week-old BALB/c nude mice, which were all obtained from BioLASCO (Taiwan). When tumours grew to an 
average volume of 200–300 mm3, prior to initiation of treatment, xenografted mice were randomized into groups 
(for grouping refer to Supplementary tables 6 & 7) based on tumour size (i.e. no individual mouse demonstrated 
more than 10% difference in tumour size group counterparts) and ANOVA performed to ensure that there were 
no statistical differences between groups. P4 and L2P4 in 0.1% DMSO at the desired dose (2 or 4 µg/tumour; low 
or high dose) were injected directly into the tumour using a 29 gauge syringe. Mice receiving an equivalent 
volume of 0.1% DMSO alone served as controls. Body weight and tumour volumes were measured twice weekly. 
Tumour volumes were calculated as (length × width2)/2. Intra-tumoural tumour injections were repeated twice 
weekly, after which the mice were sacrificed and their tumours harvested and weighed. Investigators were blind 
to the treatment groups during the experiments and data analysis. All animals were included in the analysis, no 
power analyses were used to calculate the sample size for the animal studies. All animals experiments were 






on the Use of Human and Animal Subjects in Teaching and Research and the Animal Subjects Ethics Sub-
Committee of Hong Kong Polytechnic University. 
Statistical analysis. The intensity of the protein bands and raw images were measured by Gel-Pro Analyzer to 
obtain the average of three independent experiments, showed as mean ± S.D. The results were presented as the 
column plot operated by GraphPad Prism 5.0. Single factor analysis of variance was used to detect the significance 
of difference. The absorbance of the formed formazan crystals in cytotoxicity test was measured at dual 
wavelength, 540nm and 690nm, on a Labsystem Multiskan microplate reader (Merck Eurolab, Switzerland). Each 
dosed concentration was performed in triplicate wells, and repeated twice for the MTT assay. Data were shown 
as mean ± S.D. Statistical analyses of tumour size and volume in the animal studies were conducted using the 
Student’s t-test. Results of P < 0.05 were considered significant. Data were expressed as mean ± SEM. 
Data availability 
The authors declare that all data supporting the findings of this study are available within the paper and its 
supplementary information. In addition underlying research data for this paper is also available in accordance 
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Figure 1. The rational design of the probes and the MD simulations of the designed probes to EBNA1. 
(a) The chemical structures of the designed probes (L2P2, L2P3 and L2P4). P2 is an EBNA1-specific 
peptide which is derived from 4 of EBNA1, while P3 and P4 are EBNA1-specific and nucleus-
penetrating peptides which also contain an RrRK motif in the middle (P3) or at the C-terminus (P4) of the 
sequence. The fluorescent group is always located at the N-terminus of P2, P3 and P4; (b) The suggest 
interactions between L2P4 and the putative monomer structure of EBNA1 DBD domain by rendering 
EBNA1 in ribbons (left) or electrostatic surface (right) from MD simulation. The putative structure is 
generated through the isolation of the X-ray crystal structure of EBNA1-DNA complex (PDB ID: 1B3T). 
It’s suggested that the designed probes will bind to the EBNA1 dimeric interface primarily via 
hydrophobic interactions with the YFMVF motif, and that such interactions can be enhanced by further 
electrostatic interactions with the RrRK motif; (c) The representative conformations of the designed 
probes and EBNA1 in the MD simulation. The calculated GB and PB values represented the binding free 





Figure 2. The selective and responsive signal of L2P4 upon addition of EBNA1. (a) The emission spectra of L2P4 
with 8.8-fold responsive emission enhancement and 25 nm blueshift upon addition with WT-EBNA1; (b) The 
eimission intensity change of L2, L2P2, L2P3 and L2P4 upon addition with WT-EBNA1; (c) The selectivity assay 






the confirmation of ICT state and determination of pKa value (The case of L2P3 was shown in Sup. Fig. 25). The 
emission band gradually decreased as the pH was lowered from 7 to 2. This finding is consistent with the 
characteristic of an ICT emission, which is the ICT state emision decreases at lower pHs because the nitrogen 
atoms becomes protonated in lower pHs and its lone pair is not avaliable to generate an ICT excited state; (e) The 
emission spectra of L2P4 in solvatochromism study with increasing solvent polarity; (f) Emission lifetime decay 
of L2P4 upon binding with WT-EBNA1 (upper) and solvatochromism (lower) with increasing solvent polarity 
(ex = 475 nm). Comparatively large LE emission decay and corresponding smaller ICT decay was found in less 
polar solvents, indicating a smaller dipole moment and cosequently an upshift of the ICT state. Additionaly, the 






Figure 3. In vitro imaging of the desigend probes in EBV- positive and negative cells. (a) In vitro imaging of 
L2P2, L2P3 and L2P4 in EBV-positive nasopharyngeal carcinoma C666-1 cells. (b) In vitro imaging of L2P2, L2P3 
and L2P4 in newly derived EBV-positive nasopharyngeal carcinoma NPC43 cells (ex = 488 nm, em = 500-650 
nm, Filter = BP500). C666-1 and NPC43 cells were treated with L2P2, L2P3 or L2P4 (10 M) for 6 hours, and then 





Hoechst 33342 were plotted along the green line, the shape and location of the emission band from L2P4 found 
in the nucleus (by lambda scan) was similar to the data obtained in the solution under the same excitation. (c) In 
vitro imaging of L2P2, L2P3 and L2P4 in EBV-negative (CNE2 and HeLa) and EBV-positive C666-1 cells. The 
emission of L2P4 was found to be selective in EBV-positive cells over EBV-negative cells. (d) In vitro emission 
spectra of L2P2, L2P3 and L2P4 in cell nucleus under the confocal microscope (Leica SP8). L2P4 showed three 
times stronger emission than L2P3 in the EBV-positive C666-1 cells. Scale bars were shown in the figure. 
Figure 4. a-d EBNA1 homodimerization assay. WT-EBNA1 were subjected to MBS cross-linked dimerization 






efficiency was measured by determining the protein ratio of EBNA1 dimer/ monomer (b and d), the intensity of 
each protein bands were measured by obtaining the average of three independent experiments, showed as mean 
± S.D. e-j Cytotoxicity assay. Cytotoxicity of L2P2-L2P4 on EBV-negative (e) human lung fibroblast normal 
MRC-5, (f) human cervical carcinoma HeLa, (g) Burkitt’s lymphoma Ramos cell lines and EBV-positive (h) 
nasopharyngeal carcinoma C666-1, (i) newly-derived nasopharyngeal carcinoma NPC43, (j) Burkitt’s lymphoma 
Raji cell lines were assayed. Each dosed concentration was performed in triplicate wells, and repeated twice for 
the MTT assay. Data were shown as ± S.D. (incubation time: 24 hours). 






tumour inhibition assays of P4 and L2P4; Mice were treated with intra-tumoural injections of P4, L2P4 or DMSO 
(vehicle) twice-weekly for 21 days. At the experimental endpoint, tumours were excised, weighed and 
photographed (a) Control (vehicle); (b) P4; (c) L2P4 (d) tumour volume and (e) tumour weight. Average tumour 
volume and weights from each group in mm3 and grams respectively (for grouping and measurement numbers 
refer to Sup. Table 6). Data were expressed as mean ± SEM, *, p < 0.05, **, p < 0.005, ***, p < 0.001. (f) 
Representative ex vivo fluorescence images of excised C666-1 tumours. Tumours were excised upon mouse 
sacrifice and fluorescence intensity was detected using the IVIS Lumina system 48h after intra-tumoural injection 
at 460 nm excitation/ 520 nm emission. Fluorescent signals were quantified as total radiant efficiency 
([photons/s/cm2/sr]/[µW/cm2]). Scale bars were shown in the figure. 
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